Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?

Affiliations

Editorial

Andrea Malone et al. Br J Haematol. 2017 Oct.

. 2017 Oct;179(2):179-181.

doi: 10.1111/bjh.14875. Epub 2017 Sep 10.

¹ Department of Paediatric Haematology/Oncology, Our Lady's Children's Hospital and University College Dublin, Dublin, Ireland.

No abstract available

Keywords: T-cell acute lymphoblastic leukaemia; adolescents; children; nelarabine.

Comment on

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C. Kuhlen M, et al. Br J Haematol. 2017 Oct;179(2):272-283. doi: 10.1111/bjh.14877. Epub 2017 Aug 2. Br J Haematol. 2017. PMID: 28771662 Clinical Trial.
Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, Leverger G. Zwaan CM, et al. Br J Haematol. 2017 Oct;179(2):284-293. doi: 10.1111/bjh.14874. Epub 2017 Aug 2. Br J Haematol. 2017. PMID: 28771663 Clinical Trial.